Heart Rhythm O2最新文献

{"title":"A framework for developing successful academic-industry partnerships for cardiovascular innovations","authors":"Stephanie S. Steltzer PhD ,&nbsp;Michael Ranella MBA, MPH ,&nbsp;Ingrid Qemo PhD, MBA ,&nbsp;Luciano Delbono MD ,&nbsp;C. Alberto Figueroa PhD ,&nbsp;Hamid Ghanbari MD, MPH, FACC, FHRS","doi":"10.1016/j.hroo.2025.12.010","DOIUrl":"10.1016/j.hroo.2025.12.010","url":null,"abstract":"<div><div>Cardiovascular disease remains the leading global cause of death, yet the translation of innovative technologies into clinical practice faces considerable challenges. Academic-industry partnerships offer a collaborative pathway, combining academic clinical expertise with industry resources to systematically advance cardiovascular innovation. These alliances enable the identification of unmet needs, the development and validation of novel solutions, and streamlined regulatory and commercialization processes. Despite their growing importance and the shift in research funding from federal sources to industry collaborations, inconsistent outcomes and ethical concerns persist owing to the lack of standardized partnership frameworks. This review proposes a comprehensive framework to guide successful cardiovascular academic-industry partnerships, emphasizing 5 core principles: strategic alignment, infrastructure investment, systematic assessment, graduated implementation, and robust ethical oversight. Specific partnership types and contractual agreements are discussed, along with common barriers such as divergent priorities and intellectual property conflicts. Through case study analysis and a detailed governance model, we illustrate how dedicated structures and thorough conflict management can foster trust, maximize mutual value, and accelerate patient-centered innovation. Implementing best practices ensures that these partnerships drive global cardiovascular advancements, benefiting academia, industry, and patient outcomes alike.</div></div>","PeriodicalId":29772,"journal":{"name":"Heart Rhythm O2","volume":"7 4","pages":"Pages 737-749"},"PeriodicalIF":2.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147714081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-specific impact of body mass index on recurrence of atrial fibrillation after catheter ablation","authors":"Cevher Ozcan MD ,&nbsp;Amrish Deshmukh MD ,&nbsp;Zaid Aziz MD ,&nbsp;Michael Mayer MD ,&nbsp;Hatem Al Kassem MD ,&nbsp;Jeremy Treger MD ,&nbsp;Srinath Yeshwant MD ,&nbsp;Andrew Beaser MD ,&nbsp;Gaurav Upadhyay MD ,&nbsp;Henry Huang MD, FHRS ,&nbsp;Rishi Arora MD, FHRS","doi":"10.1016/j.hroo.2026.01.024","DOIUrl":"10.1016/j.hroo.2026.01.024","url":null,"abstract":"<div><h3>Background</h3><div>Sex-specific differences in the clinical outcome of pulmonary vein isolation (PVI) in patients with atrial fibrillation (AF) remain controversial. The impact of body mass index (BMI) on sex-based variation in the outcome of PVI is not well understood.</div></div><div><h3>Objective</h3><div>We sought to investigate the impact of BMI with associated atrial conduction indices (ACIs) on sex-specific differences in AF recurrence after PVI.</div></div><div><h3>Methods</h3><div>All consecutive patients who underwent their first PVI for AF from 2014 to 2019 were included. ACIs were measured on the surface electrocardiogram and intracardiac electrogram. Data were collected and analyzed based on BMI and sex.</div></div><div><h3>Results</h3><div>The study included 387 patients with AF (121 women and 266 men; mean age <span>66</span> years; 49.2% with a BMI of ≥30 kg/m²). Women were older at the time of the procedure (median age 67 vs 62 years; <em>P</em> &lt; .001). AF recurrence was more common in women (57% vs 44.4%) during a mean 5 ± 3 years’ follow-up (<em>P</em> = .027). All-cause mortality was similar in men and women after PVI, irrespective of AF recurrence (<em>P</em> &gt; .05). Post-PVI atrial flutter (AFL) occurred more often in women (21.5% vs 10.9%; <em>P</em> = .009). Female sex, enlarged left atria, prolonged ACI, and post-PVI AFL were predictors of AF recurrence (<em>P</em> &lt; .05). High BMI and prolonged left ACI were associated with AF recurrence in women.</div></div><div><h3>Conclusion</h3><div>Female sex was associated with a higher risk of AF recurrence after PVI and post-PVI AFL. Women with high BMI and prolonged left ACI had the highest rate of AF recurrence. This highlights the importance of weight management.</div></div>","PeriodicalId":29772,"journal":{"name":"Heart Rhythm O2","volume":"7 4","pages":"Pages 675-685"},"PeriodicalIF":2.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147714652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety, performance, and remote programming utilization of an insertable cardiac monitor: The LUX-Dx PERFORM study","authors":"Mark Richards MD, PhD, FHRS ,&nbsp;John B. Garner MD ,&nbsp;John D. Rogers MD, FHRS ,&nbsp;Deepa Mahajan PhD ,&nbsp;Vasanth Ravikumar PhD ,&nbsp;Keith L. Herrmann PhD ,&nbsp;Torri Schwartz MS ,&nbsp;Brynn Okeson MS ,&nbsp;Molly E. Kupfer PhD ,&nbsp;Craig M. Stolen PhD ,&nbsp;Venkata V. Bavikati MD ,&nbsp;Jonathan W. Dukes MD, FACC ,&nbsp;Harish Manyam MD ,&nbsp;Sean D. Pokorney MD ,&nbsp;LUX-Dx PERFORM Investigators","doi":"10.1016/j.hroo.2026.01.026","DOIUrl":"10.1016/j.hroo.2026.01.026","url":null,"abstract":"<div><h3>Background</h3><div>Insertable cardiac monitors (ICMs) are designed to record subcutaneous electrocardiographic data for the diagnosis and management of arrhythmias.</div></div><div><h3>Objective</h3><div>The LUX-Dx PERFORM study evaluated the safety of the LUX-Dx ICM, the utilization of remote reprogramming, and the performance of the LUX-Dx arrhythmia detection algorithms.</div></div><div><h3>Methods</h3><div>The study included 727 patients with multiple indications for an ICM including atrial fibrillation management, syncope, and cryptogenic stroke. The primary safety endpoint was evaluated via 30-day and 12-month ICM system-related complication-free rates. Device programming changes were quantified by type and impact on episode detections. A subset of 601 patients was enrolled in a 14-day Holter study to evaluate the performance of the ICM against a third-party extended Holter monitor patch.</div></div><div><h3>Results</h3><div>ICM implants occurred in hospital (n = 547; 76%) and clinic settings (n = 170; 24%) with an extremely low 12-month complication rate (n = 3; 0.4%). Device reprogramming was performed on 184 patients (26%), with 82% of programming changes occurring remotely. Programming adjustments to reduce or enhance device detections led to an approximately 2-fold decrease or increase in monthly episodes, respectively. In the Holter substudy, the LUX-Dx identified 23 patients with atrial fibrillation episodes that were not detected by the extended Holter monitor and demonstrated 100% sensitivity for detecting pause episodes.</div></div><div><h3>Conclusion</h3><div>Fewer than 1 in 200 patients had a complication within 1 year of ICM implant, and the LUX-Dx ICM demonstrated strong arrhythmia detection performance relative to an industry-standard patch monitor. Remote programming was frequently used, which may enhance detection and streamline data processing and care in the device clinic.</div></div><div><h3>Study Identifier</h3><div>NCT04732728</div></div>","PeriodicalId":29772,"journal":{"name":"Heart Rhythm O2","volume":"7 4","pages":"Pages 695-705"},"PeriodicalIF":2.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147714656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of post-ablation chest pain: Navigating the diagnostic dilemma","authors":"Changjian He MD,&nbsp;Tianze Guo MD,&nbsp;Wenchang Zhang MD,&nbsp;Yunhe Bai MD,&nbsp;Yalei Han MD, PhD,&nbsp;Chunhua Ding MD, PhD","doi":"10.1016/j.hroo.2026.01.021","DOIUrl":"10.1016/j.hroo.2026.01.021","url":null,"abstract":"<div><div>Post-cardiac injury syndrome (PCIS) is an underrecognized inflammatory complication of atrial fibrillation ablation that can mimic acute coronary syndrome. We present a 72-year-old man who developed pleuritic chest pain and pleural effusions 3 days after radiofrequency ablation. Using the 2025 European Society of Cardiology diagnostic criteria, we identified pleural-predominant PCIS. Anti-inflammatory treatment led to rapid recovery.</div></div>","PeriodicalId":29772,"journal":{"name":"Heart Rhythm O2","volume":"7 4","pages":"Pages 802-806"},"PeriodicalIF":2.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147714674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spatiotemporal heterogeneity of activation alternans in cardiomyopathy: Implications for risk stratification with microvolt QRS alternans","authors":"Nathan C. Denham BM, PhD ,&nbsp;Adrian M. Suszko MSc ,&nbsp;Raja J. Selvaraj MD ,&nbsp;Mahbod Rahimi MSc ,&nbsp;Vijay S. Chauhan MD","doi":"10.1016/j.hroo.2026.01.011","DOIUrl":"10.1016/j.hroo.2026.01.011","url":null,"abstract":"<div><h3>Background</h3><div>Microvolt QRS alternans (QRSA) on the surface electrocardiogram is a strong predictor of ventricular arrhythmia (VA) in patients with cardiomyopathy (CM); however, its intracardiac origin has not been defined.</div></div><div><h3>Objective</h3><div>This study aimed to assess the spatiotemporal features of intracardiac activation alternans (AA) in relation to body surface QRSA and VA.</div></div><div><h3>Methods</h3><div>Unipolar electrograms were recorded from the great cardiac vein (left ventricular epicardium) and the right ventricular endocardium in 10 patients with CM (age 59 ± 16 years; left ventricular ejection fraction 32% ± 9%). Unipolar AA and surface QRSA were quantified using the spectral method during consecutive atrial pacing at 75, 100, and 120 beats per minute. AA was simulated with a 1500-node heart model to assess the relationship with surface QRSA. Patients were followed for VA over 5 years.</div></div><div><h3>Results</h3><div>AA was more prevalent in the left ventricular epicardium than the right ventricular endocardium (25% vs 5% of recording electrodes; <em>P</em> = .01) and more prevalent in the late QRS than early QRS (92% vs 69%; <em>P</em> &lt; .01). AA and QRSA were equally prevalent (62% vs 46%; <em>P</em> = .12) but AA had greater magnitude (43 [0–90] vs 0 [0–6] μV; <em>P</em> &lt; .01). AA prevalence and magnitude increased with rate but had a lower heart rate onset than QRSA. Simulated activation time alternans of 2–5 ms in a 1 cm node produced surface QRSA of similar magnitude to patients with AA. Patients with AA at 75 beats per minute were more likely to have VA in follow-up (100% vs 0%; <em>P</em> = .048).</div></div><div><h3>Conclusion</h3><div>AA exhibits substantial spatiotemporal heterogeneity in patients with CM and is dependent on heart rate. Surface microvolt QRSA is the noninvasive manifestation of intracardiac AA, which may explain its prognostic utility.</div></div>","PeriodicalId":29772,"journal":{"name":"Heart Rhythm O2","volume":"7 4","pages":"Pages 713-724"},"PeriodicalIF":2.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147714662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OPTIA-AF trial: A randomized study of rhythm-guided antithrombotic strategy after atrial fibrillation ablation in patients with prior drug-eluting stent implantation","authors":"Dong-Hyeok Kim MD, PhD ,&nbsp;Yeji Kim MD, PhD ,&nbsp;Seung Woo Lee MD ,&nbsp;Jungmin Kang MD ,&nbsp;Junbeom Park MD, PhD ,&nbsp;OPTIA-AF investigators","doi":"10.1016/j.hroo.2026.02.002","DOIUrl":"10.1016/j.hroo.2026.02.002","url":null,"abstract":"<div><h3>Background</h3><div>Recent randomized studies suggest that oral anticoagulation may be safely discontinued in carefully selected patients who maintain durable sinus rhythm (SR) after atrial fibrillation (AF) ablation. However, patients with previous drug-eluting stent (DES) implantation represent a distinct population in whom residual coronary ischemic risk persists and long-term antiplatelet therapy remains clinically relevant. The optimal antithrombotic strategy in this setting remains uncertain.</div></div><div><h3>Objective</h3><div>The Optimal Postablation Therapy for Ischemic and Arrhythmic Risk in Atrial Fibrillation (OPTIA-AF) trial was designed to evaluate whether discontinuation of non–vitamin K antagonist oral anticoagulation (NOAC) with transition to single antiplatelet therapy is noninferior to continued NOAC therapy in patients with durable SR after AF ablation and previous DES implantation.</div></div><div><h3>Methods</h3><div>OPTIA-AF is a prospective, multicenter, randomized controlled trial enrolling patients with nonvalvular AF who have maintained ≥12 months of documented SR after catheter ablation and are ≥12 months removed from DES implantation. Participants are randomized 1:1 to continued NOAC therapy or NOAC discontinuation with single antiplatelet therapy. Structured rhythm surveillance using electrocardiography and ambulatory monitoring is mandated throughout follow-up.</div></div><div><h3>Results</h3><div>The primary end point is a 24-month net clinical outcome composite of ischemic stroke, systemic embolism, myocardial infarction, definite or probable stent thrombosis, cardiovascular death, and major bleeding. Key secondary end points include individual components of the composite endpoint, clinically relevant nonmajor bleeding, AF recurrence, AF burden, arrhythmia-related hospitalization, and repeat ablation. Approximately 1000 patients will be enrolled to provide adequate power for noninferiority testing.</div></div><div><h3>Conclusion</h3><div>OPTIA-AF will provide randomized evidence to inform a rhythm-guided, individualized antithrombotic strategy after AF ablation in patients with concomitant coronary artery disease and previous DES implantation.</div></div>","PeriodicalId":29772,"journal":{"name":"Heart Rhythm O2","volume":"7 4","pages":"Pages 774-785"},"PeriodicalIF":2.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147714672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complex signal identification as a marker of left atrial remodeling and very early recurrence after atrial fibrillation ablation","authors":"Minoru Nodera MD ,&nbsp;Takashi Kaneshiro MD ,&nbsp;Sadahiro Murota MD ,&nbsp;Shinya Yamada MD ,&nbsp;Masayoshi Oikawa MD ,&nbsp;Yasuchika Takeishi MD","doi":"10.1016/j.hroo.2026.01.012","DOIUrl":"10.1016/j.hroo.2026.01.012","url":null,"abstract":"","PeriodicalId":29772,"journal":{"name":"Heart Rhythm O2","volume":"7 4","pages":"Pages 786-789"},"PeriodicalIF":2.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147714673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of impedance mapping to delineate atrial septal occluders during catheter ablation","authors":"Keita Yoshiyama MD,&nbsp;Yohei Kikuchi MD,&nbsp;Daiki Kumazawa MD,&nbsp;Kosuke Onodera MD,&nbsp;Yosuke Mizuno MD,&nbsp;Kennosuke Yamashita MD, PhD, FACC, FHRS","doi":"10.1016/j.hroo.2026.02.006","DOIUrl":"10.1016/j.hroo.2026.02.006","url":null,"abstract":"","PeriodicalId":29772,"journal":{"name":"Heart Rhythm O2","volume":"7 4","pages":"Pages 794-798"},"PeriodicalIF":2.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147714697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Same day discharge can be performed safely after atrial fibrillation catheter ablation using a wide-footprint lattice-tip dual-energy system","authors":"Tyler L. Taigen MD ,&nbsp;Devi G. Nair MD, FHRS ,&nbsp;Dinesh Sharma MD, FHRS ,&nbsp;Erich L. Kiehl MD ,&nbsp;Jose Osorio MD, FHRS ,&nbsp;Petr Neuzil MD ,&nbsp;Josef Kautzner MD ,&nbsp;Stavros E. Mountantonakis MD ,&nbsp;Andrea Natale MD, FHRS ,&nbsp;John D. Hummel MD, FHRS ,&nbsp;Shephal K. Doshi MD ,&nbsp;Anish K. Amin MD, FHRS ,&nbsp;Usman R. Siddiqui MD, FHRS ,&nbsp;Kelly A. van Bragt PhD ,&nbsp;Jeffrey Cerkvenik MSc ,&nbsp;Khaldoun G. Tarakji MD, FHRS ,&nbsp;Vivek Y. Reddy MD, FHRS ,&nbsp;Moussa Mansour MD, FHRS ,&nbsp;Elad Anter MD","doi":"10.1016/j.hroo.2026.01.015","DOIUrl":"10.1016/j.hroo.2026.01.015","url":null,"abstract":"<div><h3>Background</h3><div>Same-day discharge (SDD) after atrial fibrillation (AF) ablation is generally considered safe, since most complications are identified during (or immediately) after the procedure.</div></div><div><h3>Objective</h3><div>This study aimed to evaluate SDD in the SPHERE Persistent-Atrial Fibrillation trial.</div></div><div><h3>Methods</h3><div>Patients with persistent AF were randomized to the dual-energy lattice-tip mapping and ablation catheter (investigational) vs a conventional contact-force radiofrequency ablation system (control). SDD and timing of 30-day procedure- or device-related serious adverse events (SAEs) were assessed in the full cohort. In a subset of centers that performed SDD in the trial, predictors of SDD, 30-day readmissions, and mortality rates were assessed.</div></div><div><h3>Results</h3><div>SDD was achieved in 229 of 418 (54.8%) patients (55.9% of investigational [n = 211] and 53.6% of control [n = 207; <em>P</em> = .64]). Of the remaining patients, 181 (43.3%) were discharged the next day, whereas 8 (1.9%) were discharged 2–7 days post-ablation. A total of 11 of 14 procedure- or device-related SAEs occurred within the first 3 days post-procedure, with no relevant difference between SDD and overnight stay. In a subset of 14 centers with at least one SDD in the trial, procedure duration, procedure end time, and race predicted overnight stay (all <em>P</em> &lt; .01). All-cause 30-day readmission rates were similar between arms (<em>P</em> = .53) and discharge protocols (<em>P</em> = .19), with no deaths within 30 days.</div></div><div><h3>Conclusion</h3><div>Among the traditional thermal ablation technologies, SDD protocols have been well-established and safely practiced. Here, SDD was safely achieved, with no significant differences in outcome when performed with the investigational system compared with a conventional contact-force radiofrequency ablation system.</div></div>","PeriodicalId":29772,"journal":{"name":"Heart Rhythm O2","volume":"7 4","pages":"Pages 656-663"},"PeriodicalIF":2.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147714739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical evaluation of a spot-check ECG for the diagnosis of atrial fibrillation","authors":"Cameron Lambert MD ,&nbsp;Jay Ganji MD ,&nbsp;Ahmed Alghazi MBChB ,&nbsp;Wilson W. Good PhD ,&nbsp;Elyar Ghafoori PhD ,&nbsp;Daniel J. Cantillon MD ,&nbsp;Paul Drury MD","doi":"10.1016/j.hroo.2026.01.006","DOIUrl":"10.1016/j.hroo.2026.01.006","url":null,"abstract":"<div><h3>Background</h3><div>Opportunistic screening of atrial fibrillation (AF) using wearable spot-check electrocardiogram (ECG) devices has emerged for early detection, yet remains limited by concerns for accuracy and false positives.</div></div><div><h3>Objective</h3><div>This study aimed to assess the Masimo W1 wrist-wearable ECG spot-check device in detecting AF and normal sinus rhythm (NSR) while rendering diagnostic ECG waveform quality to support physician overread.</div></div><div><h3>Methods</h3><div>Participants with and without a previous AF diagnosis were prospectively enrolled across 4 US sites to compare the AF and NSR detection performance between the Masimo W1 ECG and a 12-lead ECG reference, plus concordance of clinically relevant ECG waveform features assessed by blinded reviewers.</div></div><div><h3>Results</h3><div>Among 356 participants (mean age 56 years; 60% female), 169 (47.5%) were in NSR and 165 (46.3%) in AF, whereas 22 were excluded as noise outputs (1.7%) or other rhythms (4.5%). Sensitivity and specificity for automated AF detection were 99.3% (95% confidence interval [CI] 96.3–100) and 100% (95% CI 97.8–100), respectively. The inconclusive rate was 5%. AF and NSR detection probabilities were 89.7% and 99.4%, respectively. Qualitative comparison demonstrated 99% (95% CI 98–100.0) agreement with the reference ECG across reviewers and records. Quantitative analysis of ECG waveform features showed a high correlation between the Masimo W1 ECG and lead I of the 12-lead ECG for diagnosing AF.</div></div><div><h3>Conclusion</h3><div>The Masimo W1 ECG demonstrated highly accurate automated AF detection, few noise classifications, and exceptional NSR detection to mitigate concerns over false positives. Qualitative preservation of ECG waveform features supports the requisite physician overread required by practice guidelines.</div></div>","PeriodicalId":29772,"journal":{"name":"Heart Rhythm O2","volume":"7 4","pages":"Pages 750-756"},"PeriodicalIF":2.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147714655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}